<DOC>
	<DOC>NCT00906698</DOC>
	<brief_summary>To determine the maximum tolerated dose, safety, pharmacokinetics and anti-tumour efficacy of oral BIBW 2992 in combination with intravenous or oral vinorelbine</brief_summary>
	<brief_title>Afatinib and Vinorelbine in Tumours Known to Overexpress EGFR and/or HER2</brief_title>
	<detailed_description />
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Inclusion criteria: Histologically or cytologically confirmed diagnosis of malignancy that is now advanced, non resectable and/or metastatic Tumours historically known to overexpress EGFR and/or HER2 Exclusion criteria: Prior treatment with HER2 inhibiting drugs within the past 4 weeks before the start of therapy or concomitantly with this trial. Prior treatment with EGFR inhibiting drugs within the past two weeks before the start of therapy or concomitantly with this trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>